ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

QGEN Qiagen NV

43.02
0.34 (0.80%)
Pre Market
Last Updated: 12:36:25
Delayed by 15 minutes
Share Name Share Symbol Market Type
Qiagen NV NYSE:QGEN NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.34 0.80% 43.02 800 12:36:25

QIAGEN Reports Results for Second Quarter and First Half of 2017

27/07/2017 4:16pm

PR Newswire (US)


Qiagen NV (NYSE:QGEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Qiagen NV Charts.

VENLO, Netherlands, July 27, 2017 /PRNewswire/ --


  • Strong Q2 2017 results reaffirm QIAGEN on track to achieve full-year goals: 
  • Net sales $349.0 million (+4% actual); adjusted net sales $349.6 million (+5% actual, +7% CER vs. +5-6% CER guidance) 
  • EPS $0.06; adjusted EPS $0.25 ($0.25 CER), adjusted EPS excluding restructuring charge $0.30 ($0.30 CER vs. $0.28-0.29 CER guidance) 
  • H1 free cash flow of $91.6 million impacted by $30.8 million for restructuring 
  • Sample to Insight portfolio momentum with expansion of QuantiFERON latent TB test, Personalized Healthcare, NGS portfolio and QIAsymphony platform 
  • QIAGEN upgrades 2017 adjusted sales outlook after solid H1, now expects 7% CER growth; keeps adjusted EPS target before restructuring of $1.25-1.27 CER 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2017, delivering on goals for improvements in net sales and adjusted earnings.

"QIAGEN's performance for the second quarter of 2017 further strengthens our confidence in achieving our full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share, as our differentiated portfolio of Sample to Insight molecular testing solutions gains momentum," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-07-27-q2results

www.twitter.com/qiagen 

www.facebook.com/QIAGEN 

Download the QIAGEN Investor Relations App

Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8

Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de

Contacts
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen.com

Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
pr.qiagen.com

SOURCE QIAGEN N.V.

Copyright 2017 PR Newswire

1 Year Qiagen NV Chart

1 Year Qiagen NV Chart

1 Month Qiagen NV Chart

1 Month Qiagen NV Chart

Your Recent History

Delayed Upgrade Clock